US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea
29/11/2023 12:39
Nov 29 (Reuters) - Vivos Therapeutics VVOS.O said on Wednesday the U.S. health regulator has cleared its oral device treatment for severe obstructive sleep apnea (OSA). (Reporting by Pratik Jain in Bengaluru; Editing by Shilpi Majumdar) ((Pratik.Jain@thomsonreuters.com;))
Recent news on Vivos Therapeutics
See all newsBrief: Vivos Therapeutics Closes Acquisition Of Stake In Sod Sciences And 50% Interest In Pseudohypoxia Test, Opening A Potential Path To Access More Than 325,000 New Patients Through The Aha Channel
Brief: Vivos Therapeutics - Audit Reports For Fy2025 And Fy2024 Include Substantial Doubt About Going Concern
Brief: Vivos Therapeutics And South Palm Cardiovascular Associates Sign Definitive Agreements To Launch Regional Sleep Testing And Treatment Center
Vivos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Vivos Therapeutics Q2 revenue rises 35% on service growth